Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275912 | 0.74 | GCGR (0.36) | PDE3BPDE3AKDM1AARPARP1 | |
| SCHEMBL10276545 | 0.73 | ALDH1A1 (0.39) | PDE3BPDE3ATDP2MAPK14 | |
| SCHEMBL10276143 | 0.72 | MAPK14 (0.33) | PDE3BPDE3AKDM1AARTDP2 | |
| SCHEMBL10275827 | 0.71 | ALDH1A1 (0.47) | MAPK14GAA | |
| SCHEMBL10276041 | 0.63 | MAPK14 (0.35) | ARMAPK14FNTAFNTBPGGT1B | |
| SCHEMBL10275285 | 0.62 | MAPK14 (0.35) | PDE3BPDE3AARMAPK14FNTA | |
| SCHEMBL10276420 | 0.62 | AR (0.34) | ARMAPK14FNTAFNTBPGGT1B | |
| SCHEMBL10275638 | 0.61 | KCNH2 (0.36) | PDE3BPDE3AKDM1AARPARP1 | |
| SCHEMBL10280465 | 0.61 | GCGR (0.40) | PDE3BPDE3AKDM1AARPARP1 | |
| SCHEMBL10275642 | 0.61 | PDE3B (0.37) | PDE3BPDE3AKDM1AARTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PDE3B 2361/4885PDE3A 2182/4885KDM1A 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.